ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010
Review of meningococcal group B vaccines.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 189 citations in OpenAlex.
- Genotypic and phenotypic comparison of Neisseria meningitidis carriage and invasive disease isolates contemporaneously collected in the Netherlands.FEMS microbiology letters · 2026Article
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Diagnosis and management strategies for an elderly patient with Neisseria meningitidis sepsis complicated by multiple organ dysfunction: A case report.SAGE open medical case reports · 2025Article
- Immunogenicity ofMembranes · 2023Article
- Review
- Bacterial extracellular vesicle applications in cancer immunotherapy.Bioactive materials · 2023Article
- Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.Human vaccines & immunotherapeutics · 2022Article
- Product review on the IMD serogroup B vaccine Bexsero®.Human vaccines & immunotherapeutics · 2022Article
- Outer Membrane Vesicles: An Emerging Vaccine Platform.Vaccines · 2022Review
- Highly Similar Sequences of Mature IgA1 Proteases fromPathogens (Basel, Switzerland) · 2022Article
- Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.The Journal of infection · 2022Article
- Whole genome sequence analysis of Neisseria meningitidis strains circulating in Kazakhstan, 2017-2018.PloS one · 2022Article
- PMAP-36 reduces the innate immune response induced byCurrent research in microbial sciences · 2021Article
- Review
- Biomimetic Bacterial Membrane Vesicles for Drug Delivery Applications.Pharmaceutics · 2021Review
- Biological Effect ofFrontiers in cellular and infection microbiology · 2021Article
- Outer Membrane Vesicle Induction and Isolation for Vaccine Development.Frontiers in microbiology · 2021Review
- Article
- Development of Different Methods for PreparingFrontiers in immunology · 2020Article
- Continuous production of Neisseria meningitidis outer membrane vesicles.Applied microbiology and biotechnology · 2019Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
No broadly effective vaccines are available for prevention of group B meningococcal disease, which accounts for >50% of all cases. The group B capsule is an autoantigen and is not a suitable vaccine target. Outer-membrane vesicle vaccines appear to be safe and effective, but serum bactericidal responses in infants are specific for a porin protein, PorA, which is antigenically variable. To broaden protection, outer-membrane vesicle vaccines have been prepared from >1 strain, from mutants with >1 PorA, or from mutants with genetically detoxified endotoxin and overexpressed desirable antigens, such as factor H binding protein. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with other antigens, are in late-stage clinical development and may be effective against the majority of group B strains. Thus, the prospects have never been better for developing vaccines for prevention of meningococcal disease, including that caused by group B strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.